| Primary Site |
Sponsor/Study ID
NTC#
|
Protocol Description |
Eligibility |
| Progressive Meningioma |
National Cancer Institute/Alliance
A071401
NCT02523014
|
Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with
SMO/ AKT/ NF2 Mutations |
- ECOG PS ≤ 2
- local diagnosis of meningioma (any grade)
- FFPE tumor block OR meningioma tissue slides available for submission to
central pathology
- Interval > 24 weeks elapsed from completion of XRT to registration
-
presence of SMO or NF2 mutation in tumor sample as documented by central
laboratory
- Must have progressive or residual disease
|
| Brain Metastasis |
NRG-CC001
NCT02360215
|
A Phase III Randomized Trials of Memantine and Whole Brain Radiotherapy
w/wo Hippocampal Avoidance in Patients With Brain Metastasis |
- KPS > 70.
- Pathologically proven diagnosis of solid tumor malignancy within 5 years
prior to step 2 registration. If greater than 5 years, pathological confirmation
from systemic metastasis or brain metastasis. Brain metastasis from primary
germ cell tumors, small cell carcinoma, unknown primary or lymphoma are
not allowed.
- Brain metastasis outside a 5 mm margin around either hippocampus must be
visible on contrast-enhanced MRI performed < or = 21 days prior to
step 1 registration.
- Prior therapy for brain metastasis is allowed including radiosurgery &
surgical resection.
- Prior external beam radiation therapy to the brain or prior whole brain
radiation therapy is not allowed
|
| Anaplastic Glioma or Low Grade Glioma |
National Cancer Institute/Alliance
N0577
NCT00887146
|
Phase II/III randomized trial of Veliparib or Placebo in combination with
adjuvant Temozolomide in newly diagnosed Glioblastoma with MGMT promoter
Hypermethylation |
- ECOG PS: 0, 1 or 2
- Newly diagnosed and ≤ 3 months from surgical diagnosis
- Histological confirmation of anaplastic glioma or low grade glioma by central
pathology review submission
- Surgery (partial or gross total resection or biopsy) performed ≥ 2 weeks
prior to registration with recovering from effects of surgery.
- Tumor must show 1p/19q codeletion
|
| Adult Glioma and Meningioma |
National Cancer Institute /Moffitt Cancer
15004
No NCT #
|
Southeastern Study of Cancer and the Environment |
- Primary diagnosis of glioma or meningioma of any grade.
- GBM dx within 1 year, Anaplastic astrocytoma grade III dx within 5 years,
grate 2 or less gliomas no restrictions.
- At least 18 years of age
- Residents of the US
|
| Brain metastases |
A221208
NCT02490878
|
Randomized Phase II study: corticosteroids + Bevacizumab Vs. Cortiscosteroids
+ Placebo (best) for radionecrosis after radiosurgery for brain metastases |
- KPS > or = 60. Symptomatic brain radionecrosis after radiosurgery for
brain metastasis from primary solid tumor including but not limited to
lung, breast, colorectal cancer, excluding melanoma, choriocarcinoma,
renal cell CA or gliomas.
- Radionecrosis at 3-24 months following radiosurgery
- New or increase headache associated with mass effect, sensory or motor
abnormality, cognitive changes, speech difficulty, balance or coordination
difficulty, cranial nerve deficits. Symptoms persistent or worsening despite
administration of at least dexamethasone 4 mg/day for 1 week.
- No Bevacizumab (Avastin) < or = 3 months of study registration. No systemic
therapy within 2 weeks prior to registration
- Central imaging review to confirm radionecrosis for eligibility
|
| Recurrent Anaplastic Astrocytoma |
Orbus therapeutics
STELLAR
OT-15-001
NCT02796261
|
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety
of Eflornithine with Lomustine Compared to Lomustine Alone in Patients
with Anaplastic Astrocytoma That Progress/Recur After Irradiation and
Adjuvant Temozolomide Chemotherapy. |
- KPS > 70
- Surgical or biopsy-proven diagnosis of WHO grade 3 AA
- Stained, unstained slides or tumor tissue block(s) are available from their
most recent tumor surgery for central histological confirmation
- Completion of EBRT ≥ 6 months prior to randomization
- Life expectancy ≥ 6 months
|
| Brain Tumor |
A221101 NCI
NCT01781468
|
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil
(Nuvigil®) To Reduce Cancer Related Fatigue in Patients With High
Grade Glioma |
- ≥ 18 years
- Clinical stable and completed radiation therapy
- Symptoms of fatigue related to tumor treatment
|
| Brain Metastasis |
NRG-CC001
NCT02360215
|
A Phase III Randomized Trials of Memantine and Whole Brain Radiotherapy
w/wo Hippocampal Avoidance in Patients With Brain Metastasis |
- Brain metastasis
- Able to have MRI scan
- Prior therapy for brain metastasis allowed (surgical resection/radiosurgery)
|
| Re-Current GBM |
Medicenna Biopharma Inc.
MDNA55-05
NCT02858895
|
An Open-Label Non-Randomized Multi-Center Phase-2 Study of Convection-Enhanced
Delivery (CED) of MDNA55 in Adults with Glioblastoma at First or Second
Recurrence or Progression |
- KPS >or = 70. Life expectancy of at least 12 weeks
- Histologically confirmed primary GBM - de novo- that has recurred or progressed
(first or second recurrence, including this recurrence) after treatment
including surgery & radiotherapy with or without chemotherapy.
- More than 12 weeks since completion of radiation therapy at time of study entry
-
Access to archival tissue from 1st diagnosis of GBM
- Recurrent tumor must be a solid, supratentorial, contrast enhancing GB
no smaller than 1x1 cm and no larger than 4 cm max. in a single diameter
based on MRI taken within 14 days prior to catheter placement.
|